Angelica C. Kottkamp
A5058809804- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- SARS-CoV-2 detection and testing
- Poxvirus research and outbreaks
- Bacillus and Francisella bacterial research
- Immunotherapy and Immune Responses
- Vaccine Coverage and Hesitancy
- Animal Virus Infections Studies
- Long-Term Effects of COVID-19
- Mosquito-borne diseases and control
- RNA Interference and Gene Delivery
- COVID-19 and Mental Health
- Virus-based gene therapy research
- Herpesvirus Infections and Treatments
- Virology and Viral Diseases
- COVID-19 epidemiological studies
- Viral Infections and Vectors
- Parasites and Host Interactions
- vaccines and immunoinformatics approaches
- LGBTQ Health, Identity, and Policy
- Advanced biosensing and bioanalysis techniques
- Antifungal resistance and susceptibility
- Viral gastroenteritis research and epidemiology
- Global Maternal and Child Health
- Vitamin C and Antioxidants Research
New York University
2018-2025
Bellevue Hospital Center
2021-2023
Manhattan Psychiatric Center
2023
New York City Health and Hospitals Corporation
2023
Manhattan Institute for Policy Research
2023
University School
2018
Although the three vaccines against coronavirus disease 2019 (Covid-19) that have received emergency use authorization in United States are highly effective, breakthrough infections occurring. Data needed on serial of homologous boosters (same as primary vaccine) and heterologous (different from fully vaccinated recipients.In this phase 1-2, open-label clinical trial conducted at 10 sites States, adults who had completed a Covid-19 vaccine regimen least 12 weeks earlier no reported history...
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost generate protective immunity. We assess the magnitude and short-term durability antibodies after homologous heterologous boosting with mRNA Ad26.COV2.S vaccines. All prime-boost combinations substantially increase neutralization titers Omicron, although boosted decline rapidly within months from peak response...
<h3>Importance</h3> The SARS-CoV-2 viral trajectory has not been well characterized in incident infections. These data are needed to inform natural history, prevention practices, and therapeutic development. <h3>Objective</h3> To characterize early RNA load (hereafter referred as load) individuals with infections association COVID-19 symptom onset severity. <h3>Design, Setting, Participants</h3> This prospective cohort study was a secondary analysis of remotely conducted that enrolled 829...
While Coronavirus disease 2019 (Covid-19) vaccines are highly effective, breakthrough infections occurring. Booster vaccinations have recently received emergency use authorization (EUA) for certain populations but restricted to homologous mRNA vaccines. We evaluated and heterologous booster vaccination in persons who had an EUA Covid-19 vaccine regimen. In this phase 1/2 open-label clinical trial conducted at ten U.S. sites, adults one of three least 12 weeks prior enrollment no reported...
Effective prevention against coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome 2 (SARS-CoV-2), is currently limited to nonpharmaceutical strategies. Laboratory and observational data suggested that hydroxychloroquine had biological activity SARS-CoV-2, potentially permitting its use for prevention.
Vaccine protection against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection wanes over time, requiring updated boosters. In a phase 2, open-label, randomized clinical trial with sequentially enrolled stages at 22 US sites, we assessed safety and immunogenicity of second boost monovalent or bivalent variant vaccines from mRNA protein-based platforms targeting wild-type, Beta, Delta Omicron BA.1 spike antigens. The primary outcome was pseudovirus neutralization titers 50%...
As part of a multicenter study evaluating homologous and heterologous COVID-19 booster vaccines, we assessed the magnitude, breadth, short-term durability binding pseudovirus-neutralizing antibody (PsVNA) responses following single dose NVX-CoV2373 in adults primed with either Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccines. as was immunogenic associated no safety concerns through Day 91. Fold-rises PsVNA titers from baseline (Day 1) to 29 were highest for prototypic D614G variant lowest more...
ABSTRACT Background Protection from SARS-CoV-2 vaccines wanes over time and is compounded by emerging variants including Omicron subvariants. This study evaluated safety immunogenicity of variant vaccines. Methods phase 2 open-label, randomized trial enrolled healthy adults previously vaccinated with a primary series single boost. Eligible participants were to one six Moderna COVID19 mRNA vaccine arms (50µg dose): Prototype (mRNA-1273), BA.1+Beta (1 or doses), BA.1+Delta, BA.1 monovalent,...
The Omicron variant of SARS-CoV-2 exhibits reduced susceptibility to vaccine-induced neutralizing antibodies, requiring a boost generate protective immunity. Little is known about the durability vaccine-boosted omicron antibodies and potential impact boosting with heterologous vaccine modalities. We assessed magnitude short-term after homologous mRNA Ad26.COV2.S vaccines. Using pseudovirus live virus neutralization assays, all prime-boost combinations substantially increased titers although...
Abstract In a randomized clinical trial, we compare early neutralizing antibody responses after boosting with bivalent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA) vaccines based on either BA.1 or BA.4/BA.5 Omicron spike protein combined wild-type spike. Responses against SARS-CoV-2 variants exhibited the greatest reduction in titers currently circulating subvariants for both vaccines.
The ability to protect vulnerable populations such as pregnant women and children from Zika virus other arbovirus infections is essential preventing the devastating complications induced by these viruses. One class of antiviral therapies may lie in known pregnancy-acceptable drugs that have potential mitigate disease, yet this has not been explored detail. In study, we show common antiparasitic drug atovaquone inhibits replication through intracellular nucleotide depletion can impair ZIKV...
Abstract The coronavirus disease 2019 (COVID-19) pandemic has disproportionately impacted lesbian, gay, bisexual, transgender, and queer (LGBTQ+) communities. Many disparities mirror those of the human immunodeficiency virus (HIV)/AIDS epidemic. These health inequities have repeated throughout history due to structural oppression LGBTQ+ people. We aim demonstrate that familiar patterns reflect a perpetuating, deeply rooted cycle injustice imposed on Here, we contextualize COVID-19 through...
Abstract Background The 2022 global outbreak of clade IIb mpox, the first significant occurrence outside Africa, led to vaccination campaigns using third-generation orthopoxvirus vaccine modified vaccinia Ankara, Bavarian Nordic (MVA-BN or JYENNEOS vaccine). In US, a one-fifth dose an intradermal regimen MVA-BN was authorized as dose-sparing alternative two-dose subcutaneous licensed in 2019. During campaign, we launched New York City Observational Study Mpox Immunity (NYC OSMI) which...
ABSTRACT The 2022 global outbreak of clade IIb mpox was the first major outside African nations. To control outbreak, public health officials began vaccination campaigns using third-generation orthopoxvirus vaccine modified vaccinia Ankara from Bavarian Nordic (MVA-BN). Prior to this durability monkeypox virus (MPXV)-specific immunity induced by MVA-BN poorly understood. In 2022, we launched New York City Observational Study Mpox Immunity (NYC OSMI, NCT05654883), a longitudinal study 171...
Abstract Background Mucosal immunity plays a critical role in preventing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and replication. Understanding the capacity of disease 2019 (COVID-19) vaccines to elicit both mucosal systemic antibodies could help optimize vaccination strategies. Methods We conducted an open-label, phase 1/2 adaptive-design clinical trial evaluate safety immunogenicity COVID-19 immunizations. Healthy adults received priming doses mRNA-1273,...
Abstract The 2022 global outbreak of clade IIb mpox was the first major outside African nations. To control outbreak, vaccination campaigns were begun using third-generation orthopoxvirus vaccine MVA-BN. During campaign, we launched New York City Observational Study Mpox Immunity (NYC OSMI). NYC OSMI is a longitudinal study that enrolled 171 MVA-BN vaccinees with or without prior smallpox and convalescent individuals. participants had blood drawn to vaccination, after one dose, two doses....
Epidemic RNA viruses seem to arise year after leading countless infections and devastating disease. SARS-CoV-2 is the most recent of these viruses, but there will undoubtedly be more come. While effective vaccines are being deployed, one approach that still missing antivirals can used at onset therefore prevent pandemics. Here, we screened FDA-approved compounds against SARS-CoV-2. We found atovaquone, a pyrimidine biosynthesis inhibitor, able reduce infection in human lung cells. In...
Vaccine protection against COVID-19 wanes over time and has been impacted by the emergence of new variants with increasing escape neutralization. The Variant Immunologic Landscape (COVAIL) randomized clinical trial (clinicaltrials.gov NCT05289037) compares breadth, magnitude durability antibody responses induced a second vaccine boost mRNA (Moderna mRNA-1273 Pfizer-BioNTech BNT162b2), or adjuvanted recombinant protein (Sanofi CoV2 preS DTM-AS03) monovalent bivalent candidates targeting...
For COVAIL recipients of a coronavirus disease 2019 (COVID-19) Sanofi booster vaccine, neutralizing antibody titers were assessed as correlate risk (CoR) COVID-19. Peak and exposure-proximal inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
While detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by diagnostic reverse-transcription polymerase chain reaction (RT-PCR) is highly sensitive for viral RNA, the nucleic acid amplification subgenomic RNAs (sgRNAs) that are product replication may more accurately identify replication. We characterized RNA and sgRNA RT-PCR from nasal swab samples collected daily participants in postexposure prophylaxis or treatment studies SARS-CoV-2. Among 1932 RT-PCR-positive with...
The 2022 mpox outbreak in New York City posed challenges to rapidly scaling up treatment capacity. We describe a telehealth model launched during this that facilitated healthcare provider capacity, and was able adhere Centers for Disease Control Prevention (CDC)-sponsored expanded access investigational new drug (EA-IND) protocol tecovirimat. Sixty-nine patients were evaluated prescribed tecovirimat through visits at NYC Health + Hospitals/Bellevue NYU Langone from June August 2022....
BACKGROUND:Cryptococcal meningitis in patients who are seronegative for the human immunodeficiency virus (HIV) and splenectomized is rare. This report an unusual case of meningeal cerebellar infection due to encapsulated yeast, Cryptococcus neoformans, which has not previously been associated with asplenia. CASE REPORT:A 65-year-old HIV-negative patient a previous splenectomy, presented three-day history fever, vomiting, headache. His symptoms progressed generalized body aches, persistent...